Gefitinib (GMP)

Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor[1][2].

Product Specifications

CAS Number

[184475-35-2]

Product Name Alternative

ZD1839 (GMP)

UNSPSC

12352005

Hazard Statement

H302, H315, H318, H351, H360, H373, H410

Target

Apoptosis; Autophagy; EGFR

Type

GMP Small Molecules

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gefitinib-gmp.html

Purity

100.00

Solubility

10 mM in DMSO

Smiles

ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F

Molecular Formula

C22H24ClFN4O3

Molecular Weight

446.90

Precautions

H302, H315, H318, H351, H360, H373, H410

References & Citations

[1]Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62 (20) :5749-54. |[2]Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28 (1) :50. |[3]Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2 (3) :e39.